People, every show

Joshua Meier

Co-founder & CEO, Chai Discovery. On 1 show, 1 appearance. The Shows tab opens the full record on each.

founderexecutivescientist@joshim5 ↗LinkedIn ↗chaidiscovery.com ↗

Joshua Meier is the co-founder and CEO of Chai Discovery, a biotech startup developing foundation AI models to predict biochemical interactions and design therapeutic antibodies. He previously served as Chief AI Officer at Absci and conducted AI research at Meta FAIR and OpenAI.

What they said6 Shows1

Everything Joshua Meier said on any show that made the record, most notable first. Each card names its show and opens the statement there.

NO PRIORS Assertion Supported

Meier: Chai-2 maintains success rate on targets with 25% sequence similarity

“We actually even have a slide in our paper in the supplement where we actually look at an even harder subset. So not looking at things that are, you know, up to a sequence similarity with the model, but actually pushing all the way down to 25%. So really looki…”

Joshua Meier Jul 3, 2025 ▶ 17:23 No Priors Ep. 121 | With Chai Discovery Co-Founders Jack Dent and Joshua Meier

NO PRIORS Prediction Not checkable as stated

Meier: Clinical interest in traditional monoclonal antibodies will decline

“So what we predict will happen is people probably won't be as interested in, in the clinic for things like monoclonal antibodies. These are, you know, antibodies that are hitting, for example, like a specific epitope on a protein.”

Joshua Meier Jul 3, 2025 ▶ 27:43 No Priors Ep. 121 | With Chai Discovery Co-Founders Jack Dent and Joshua Meier

NO PRIORS Opinion

Meier: Previous AI bio startups had overly tight lab integration

“Almost every AI bio company before us has had some kind of very tight lab integration with what they are doing. And it almost too tight.”

Joshua Meier Jul 3, 2025 ▶ 3:05 No Priors Ep. 121 | With Chai Discovery Co-Founders Jack Dent and Joshua Meier

NO PRIORS Assertion Not checkable as stated

Meier: Most AI drug discovery papers test only one to three targets

“Most of the existing papers in this area of doing AI for drug discovery are usually looking at like one, two or three targets.”

Joshua Meier Jul 3, 2025 ▶ 10:40 No Priors Ep. 121 | With Chai Discovery Co-Founders Jack Dent and Joshua Meier

NO PRIORS Assertion Supported

Meier: Chai-2 achieved a 50% success rate on tested targets

“The model is not perfect. You know, it worked in 50% of the targets that we tried. Maybe it would have been more, right, for the caveats we talked about before, but, you know, it worked in 50% of cases.”

Joshua Meier Jul 3, 2025 ▶ 18:50 No Priors Ep. 121 | With Chai Discovery Co-Founders Jack Dent and Joshua Meier

NO PRIORS Disclosure

Chai filtered benchmark targets to under 70% identity from training data

“So we actually wrote a scraper that would go and see what was in stock. We would go and pick out the protein. We would go look at what that protein sequence was. Now we need to make sure this is held out from training as well. Right? So we would take that, tha…”

Joshua Meier Jul 3, 2025 ▶ 11:39 No Priors Ep. 121 | With Chai Discovery Co-Founders Jack Dent and Joshua Meier

One line per show, most statements first. The link opens Joshua's full record on that show: the calibration, argument clarity, speaking style and every statement made there.

Show	Role there	Eps	Statements	Record
NO PRIORSLEDGER	Co-founder & CEO, Chai Discovery	1	6	100% 2/2	full record on No Priors →